PerpEquities
BingX
Gate.io
ExtendedReference market
Closed- Regular hours
- 09:30 AM – 04:00 PM
- Next holiday
- Nov 26, 2026 · Thanksgiving Day
Equity · Healthcare
Vertex Pharmaceuticals (VRTX) perpetual futures
VRTX perpetual futures on 3 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade VRTXUSDT.
Vertex Pharmaceuticals is a biotechnology company focused on discovering and marketing innovative treatments for cystic fibrosis and other serious diseases including diabetes, kidney disease, and sickle cell disease.
$519.48+0.2%NASDAQ closed
Price chart
–
Use the left and right arrow keys to inspect points on the chart.
Collecting venue price data...
venue perp mark · BingX (VRTXUS-USDT)
Auto: highest-volume live perp venueOpen in TradingView
Trading data
Perpetual market activity
3/3 live markets
Trading data
Perpetual market activity
Venues
3
Live markets
3/3
24h volume
$1.6KCoverage: 2/3 marketsExchange-reported volume: $1.2M
Open interest
$5.1K
Best liquidity
$3.4K
BingX
Tightest spread
+20.6 bps
BingX
Highest volume
$1.6K
Gate.io
Settlement mix
USDT · 2/3
Perp/spot vol.
0.00x
Spot volume $454.9M
OI / float
0.00%
Float $131.6B
Spot performance
1D+0.17%
5D-2.68%
1M-0.19%
6M+9.82%
YTD+13.69%
1Y+31.09%
Venue matrix
3 markets
Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.
Tokenized wrappers of the real stock, tradable on-chain and on crypto exchanges around the clock. Premium/discount compares the token price to our stock reference price. Data: CoinMarketCap · Robinhood · DexScreener · GeckoTerminal.
| Product | Price | Premium vs stock | 24h Vol. | Market Cap | Chains |
|---|---|---|---|---|---|
| VRTXonOndo GM | $516.22 | -0.63% | $46k | $7k | Solana · Ethereum · BNB Smart Chain (BEP20) |
| VRTxxStocks | $248.39 | -52.18% | $12k | $520k | Solana · Ethereum · Mantle · Ink |
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100k
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100kNo sufficient depth · 0 of 3 venues absorb $10k
Too thin: BingX
No fresh book data: Gate.io, Extended
Taker execution estimate incl. approx. fees - maker fills are not guaranteed.
Best venues for this underlying
Best liquidity
VRTXTightest spread
VRTXHighest volume
VRTXFunding history
Stored venue snapshots by market
Funding history
Stored venue snapshots by marketCompany data
Company fundamentals
Updated 2h ago
Company data
Company fundamentals
Market cap
$130.8B
Updated 2h ago
Revenue
$12.6B
Trailing 12 months
Revenue growth
+10%
Next fiscal year
Profit margin
+34.9%
P/E
29.8
Peer P/E 18.0
Free cash flow
$3.8B
Trailing 12 months
More metrics
Net income
$4.4B
Trailing 12 months
P/S
10.4
Peer P/E
18.0
Similar listed perps
Revenue estimate
$13.2B
Next fiscal year
Earnings
2026-11-02
Revenue est. $3.4B · Updated 2h ago
Dividend
-
Fundamental detail
Annual + quarterlyLatest revenue$12.1B
Net margin+32.7%
Free cash flow$3.2B
Net debt-$1.2B
PeriodRevenueGrowthNet incomeFCF
2020$6.2B+49%$2.7B$3B
2021$7.6B+22%$2.3B$2.4B
2022$8.9B+18%$3.3B$3.9B
2023$9.9B+11%$3.6B$3.3B
2024$11B+12%-$535.6M-$790.3M
2025$12.1B+10%$4B$3.2B
PeriodGross marginOperating marginNet marginROEROA
2020+88.1%+46.0%+43.7%+31.2%+23.1%
2021+88.1%+36.7%+30.9%+23.2%+17.4%
2022+87.9%+48.2%+37.2%+23.9%+18.3%
2023+87.2%+38.8%+36.7%+20.6%+15.9%
2024+86.1%-2.1%-4.9%-3.3%-2.4%
2025+85.0%+39.4%+32.7%+21.2%+15.1%
PeriodCashDebtNet debtCurrent ratio
2020$6B$931.9M-$5.1B4.33
2021$6.8B$967.4M-$5.8B4.46
2022$10.5B$899.7M-$9.6B4.83
2023$10.4B$808.4M-$9.6B3.99
2024$4.6B$1.7B-$2.8B2.69
2025$5.1B$3.9B-$1.2B2.90
PeriodMarket capEnterprise valueP/SP/E
2020$61.4B$56.4B9.922.6
2021$56.6B$50.8B7.524.2
2022$74B$64.4B8.322.3
2023$104.9B$95.3B10.629.0
2024$103.7B$100.9B9.4-193.6
2025$115.9B$114.7B9.629.3
PeriodRevenueGrowthNet incomeFCF
Q3 2024$2.8B+12%$1B$1.3B
Q4 2024$2.9B+16%$913M$492M
Q1 2025$2.8B+3%$646.3M$778.2M
Q2 2025$3B+12%$1B$927.4M
Q3 2025$3.1B+11%$1.1B$1.1B
Q4 2025$3.2B+11%$1.2B$348.6M
Q1 2026$3B+8%$1B$1.3B
Q2 2026$3.3B+12%$1.1B$1B
PeriodGross marginOperating marginNet marginROEROA
Q3 2024+85.8%+40.3%+37.7%+6.7%+4.7%
Q4 2024+85.5%+35.2%+31.4%+5.6%+4.1%
Q1 2025+86.9%+22.7%+23.3%+3.9%+2.8%
Q2 2025+86.3%+38.8%+34.8%+6.0%+4.3%
Q3 2025+86.5%+38.6%+35.2%+6.3%+4.4%
Q4 2025+85.6%+40.3%+36.9%+6.4%+4.6%
Q1 2026+86.8%+38.1%+34.5%+5.3%+3.9%
Q2 2026+85.3%+37.4%+33.0%+5.4%+4.0%
PeriodCashDebtNet debtCurrent ratio
Q3 2024$5.2B$1.7B-$3.5B2.47
Q4 2024$4.6B$1.7B-$2.8B2.69
Q1 2025$4.7B$1.6B-$3B2.65
Q2 2025$5B$1.5B-$3.4B2.52
Q3 2025$4.9B$1.8B-$3.1B2.36
Q4 2025$5.1B$3.9B-$1.2B2.90
Q1 2026$5.5B$2B-$3.5B3.02
Q2 2026$6.1B$2B-$4.2B3.19
PeriodMarket capEnterprise valueP/SP/E
Q3 2024$120B$116.5B43.328.7
Q4 2024$103.7B$100.9B35.628.4
Q1 2025$124.6B$121.5B45.048.1
Q2 2025$114.3B$110.8B38.527.7
Q3 2025$100.1B$97B32.523.1
Q4 2025$115.1B$113.9B35.724.2
Q1 2026$113.5B$110B38.027.5
Q2 2026$126.1B$122B37.828.7
Refreshed 2h ago
Charts: revenue, profit, cash flow & valuation
CashDebt
Gross marginOperating marginNet margin
P/EP/S
CashDebt
Gross marginOperating marginNet margin
P/EP/S
Next catalyst
Catalysts
Next catalyst
Catalysts
Earnings
2026-11-02
Revenue est. $3.4B · Updated 2h ago
No unusual perp activity right now.
FMP reference data
Market context
FMP reference data
Market context
NASDAQ
After-hours reference
Bid513.67
Ask529.19
Volume875,635
Research data
Analysts, filings and peer context
Research data
Analysts, filings and peer context
Estimates
6DateEPS estimateRevenue estimateGrowthAnalysts
FY 202618.68$13.2B+10%11
FY 202721.15$14.6B+21%11
FY 202825.27$16.4B+36%7
FY 202930.21$18.4B+53%2
FY 203034.10$20.2B+67%4
Q1 20274.69$3.4B+13%6
Company events
62026-11-02EarningsActual - / Estimate 4.77-
2026-08-03EarningsActual 4.73 / Estimate 4.74Miss
2026-05-04EarningsActual 4.47 / Estimate 4.24Beat
2026-02-12EarningsActual 5.03 / Estimate 5.11Miss
2025-11-03EarningsActual 4.8 / Estimate 4.57Beat
2025-08-04EarningsActual 4.52 / Estimate 4.29Beat
Peer comparison
Similar listed perpsRevenue mix
PendingSegment data is not available yet.
Analysts
PendingNo analyst data available yet.
Ownership
VRTX-PERPOwnership data is being populated.
Filings
PendingNo filings available yet.
Transcripts
PendingNo transcripts available yet.
Latest updates
No recent updates available.No recent updates available.
FMP company data
Company intelligence
Updated: Sep 14, 2026, 02:22 AM UTC
FMP company data
Company intelligence
Company profile
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Reshma Kewalramani
- Employees
- 6,400
- IPO date
- Jul 24, 1991
- Country
- US
- Exchange
- NASDAQ Global Select
Altman Z-scorei13.19
Piotroski scorei5/9
FMP ratingiB+
Owner earningsi$1.09B$4.25 per share
ESG risk ratingiB-Industry rank: 723 out of 724
Rating factors
- Return on equityi
- 5
- Return on assetsi
- 5
- Debt to equityi
- 3
- Price to earningsi
- 1
- Price to booki
- 1
Company press releases
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership TeamBusiness WireVertex to Participate in Upcoming September Investor ConferencesBusiness WireCrinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNXBusiness WireVertex Reports Second Quarter 2026 Financial ResultsBusiness WireCrinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNXBusiness WireVertex to Announce Second Quarter 2026 Financial Results on August 3rdBusiness Wire
Congressional disclosures
Senate
Alan ArmstrongPurchase · $1,001 - $15,000Disclosed: Jul 22, 2026Thomas Hawley TubervilleSale (Full) · $1,001 - $15,000Disclosed: Jun 14, 2024Tommy TubervilleSale (Full) · $1,001 - $15,000Disclosed: Jun 14, 2024Thomas Hawley TubervillePurchase · $1,001 - $15,000Disclosed: Nov 10, 2022Tommy TubervillePurchase · $1,001 - $15,000Disclosed: Nov 10, 2022
House
David TaylorSale · $1,001 - $15,000Disclosed: Sep 7, 2026David J. TaylorSale (Full) · $1,001 - $15,000Disclosed: Sep 7, 2026Ro KhannaPurchase · $1,001 - $15,000Disclosed: May 13, 2026David J. TaylorSale · $1,001 - $15,000Disclosed: Feb 3, 2026David TaylorSale · $1,001 - $15,000Disclosed: Feb 3, 2026
Market cap history
$130.87B+14.3%Jun 26 – Sep 26
Latest: $130.87B · 2026-09-11High: $139.03B · 2026-08-24Low: $114.46B · 2026-06-15
Largest fund holders
| Fund | Weight | Shares held |
|---|---|---|
| VTI | 0.17% | 8.1M |
| VOO | 0.19% | 6.7M |
| QQQ | 0.58% | 5.4M |
| IVV | 0.2% | 3.3M |
| XAW.TO | 0.12% | 3.3M |
| SPY | 0.2% | 3.1M |
| FXAIX | 0.19% | 3M |
| VUG | 0.35% | 2.8M |
| VGHAX | 2.41% | 1.9M |
| XLV | 2.19% | 1.8M |
| IBB | 7.94% | 1.6M |
| VIIIX | 0.19% | 1.4M |
Analyst track record
How the analysts covering VRTX have done: ratings, price-target accuracy and the measured reaction after their calls.
| 12 months | 3 years | |
|---|---|---|
| Ratings | 231 | 734 |
| Analysts | 36 | 50 |
| Buy / hold / sell | 188 / 42 / 1 | 495 / 219 / 20 |
| Upgrades / downgrades / initiations | 8 / 0 / 4 | 13 / 12 / 16 |
| Price targets hit / missed | 43 / 150 (22%) | 318 / 291 (52%) |
| Avg. return after a rating (TipRanks) | -4.9% | +5.6% |
| Best / worst call | +47.0% / -23.4% | +63.4% / -23.4% |
After buy calls on this stock: median 21-day move +1.6% vs S&P 500 +0.4% (n = 490)
Most accurate on this stock
Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.
- Gena WangBarclays100% hit rate on this stock · 12 targets measuredHoldtarget $414Nov 10, 2025
- Jessica FyeJ.P. Morgan83% hit rate on this stock · 12 targets measuredBuytarget $560Sep 11, 2026
- Andrew FeinH.C. Wainwright50% hit rate on this stock · 16 targets measuredBuytarget $641Aug 4, 2026
Latest ratings
| Date | Analyst | Call | Target | |
|---|---|---|---|---|
| Sep 11, 2026 | Jessica FyeJ.P. Morgan | BuyInitiated | $560 | article ↗ |
| Sep 2, 2026 | Geoff MeachamCiti | BuyMaintained | $585 | article ↗ |
| Sep 1, 2026 | Terence FlynnMorgan Stanley | BuyInitiated | $665 | article ↗ |
| Aug 20, 2026 | Michael YeeUBS | BuyReiterated | $585 | article ↗ |
| Aug 17, 2026 | Evan SeigermanBMO Capital | BuyMaintained | $600 | article ↗ |
Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.
TipRanks data via FMP · computed Sep 11, 2026 · 231 ratings
Frequently asked questions
Where can I trade VRTX perpetual futures?
Vertex Pharmaceuticals (VRTX) perpetual futures trade on 3 crypto venues, including BingX, Gate.io, Extended. PerpEquities compares them by live price, funding rate, open interest and liquidity.
Can I trade VRTX around the clock?
Yes. Unlike the underlying stock, VRTX perpetuals trade 24/7 — including weekends and outside regular market hours.
What is the funding rate on VRTX perpetuals?
Right now the VRTX perp funding rate is +4.4% annualized (venue median), ranging from 0.0% to +5.5% across 3 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.
How does the VRTX perp price compare to the Vertex Pharmaceuticals stock?
The venue-median VRTX perp mark is $517.3 versus a reference stock price of $519.5, a basis of -0.4%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.
What is a VRTX perpetual future?
A VRTX perpetual is a derivative that tracks the price of Vertex Pharmaceuticals with no expiry date. It lets you take long or short exposure to Vertex Pharmaceuticals on crypto venues, around the clock.
What is VRTXUSDT perpetual?
VRTXUSDT is the symbol most crypto exchanges use for the Vertex Pharmaceuticals perpetual settled in USDT (Tether). It tracks the VRTX share price through an index, trades 24/7 with leverage and never expires.
Embed this asset
<a href="https://perpequities.com/stocks/vrtx-perp"><img src="https://perpequities.com/badge/vrtx-perp.svg" width="240" height="64" alt="VRTX perpetuals · perpequities.com" loading="lazy"></a>